Evidence map›Paper›PMID 28918518›Full record

ArticleStem cell reviews and reports2017

Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis.

Juliana Barrera-Ramirez, Jessie R Lavoie, Harinad B Maganti, William L Stanford, Caryn Ito, Mitchell Sabloff, Marjorie Brand, Michael Rosu-Myles, Yevgeniya Le, David S Allan

Open access · hybridAbstract read
In one paragraph

Article in Stem cell reviews and reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. The theragnostic advances of exosomes in managing leukaemia.Journal of cellular and molecular medicine · 2024
    Review
  7. Review
  8. Article
  9. Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Cancers · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Juliana Barrera-RamirezRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Jessie R LavoieCentre for Biologics Evaluation, Biologics Genetic and Therapies Directorate, Health Products Food Branch, Health Canada, Ottawa, ON, Canada.
Harinad B MagantiRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
William L StanfordRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Caryn ItoRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mitchell SabloffHematology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada.
Marjorie BrandRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Michael Rosu-MylesCentre for Biologics Evaluation, Biologics Genetic and Therapies Directorate, Health Products Food Branch, Health Canada, Ottawa, ON, Canada.
Yevgeniya LeRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
David S AllanRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. daallan@ohri.ca.
University of Ottawa · CAHealth Canada · CAOttawa Hospital · CAOttawa Institute of Systems BiologyCanadian Nuclear Laboratories · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene regulatory networks in AML may be influenced by microRNAs (miRs) contained in exosomes derived from bone marrow mesenchymal stromal cells (MSCs). We sequenced miRs from exosomes isolated from marrow-derived MSCs from patients with AML (n = 3) and from healthy controls (n = 3; not age-matched). Known targets of mIRs that were significantly different in AML-derived MSC exosomes compared to controls were identified. Of the five candidate miRs identified by differential packaging in exosomes, only miR-26a-5p and miR-101-3p were significantly increased in AML-derived samples while miR-23b-5p, miR-339-3p and miR-425-5p were significantly decreased. Validation of the predicted change in gene expression of the potential targets was investigated by interrogating gene expression levels from public datasets of marrow-derived CD34-selected cells from patients with AML (n = 69) and healthy donors (n = 40). Two molecules with decreased gene expression in AML (EZH2 and GSK3β) were predicted by the miR profiling and have been previously implicated in AML while three molecules were increased in AML-derived cells and have not been previously associated with leukemogenesis (KRBA2, RRBP1 and HIST2H 2BE). In summary, profiling miRs in exosomes from AML-derived MSCs allowed us to identify candidate miRs with potential relevance in AML that could yield new insights regarding leukemogenesis or new treatment strategies.

Indexed as

AdultAgedBone Marrow CellsCarcinogenesisCell DifferentiationExosomesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteMaleMesenchymal Stem CellsMicroRNAsMiddle AgedNeoplasm ProteinsMicroRNAsNeoplasm ProteinsAcute myeloid leukemiaBone marrowExosomeMesenchymal stromal cellsMicroRNA

Identifiers

PMID28918518
PMCPMC5730624
OpenAlexW2754123122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.